医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2013年
27期
13-14
,共2页
2型糖尿病%新发%胰岛素泵%强化治疗%远期疗效
2型糖尿病%新髮%胰島素泵%彊化治療%遠期療效
2형당뇨병%신발%이도소빙%강화치료%원기료효
Type 2 diabetes%Newly diagnosed%Insulin pump%Intensive treatment%long-term effect
目的比较胰岛素泵（CSI ）与胰岛素多次皮下注射（MSI ）治疗新发2型糖尿病患者远期临床效果。方法将66例初诊T2DM住院患者随机分为两组，CSI 组与MSI 组，每组33例。CSI 组用胰岛素泵持续皮下注射重组人胰岛素优必林R，MSI 组予三餐前优必林R，睡前注射长秀霖；治疗2周后，改为门诊口服降血糖药物治疗6个月。观察两组空腹血糖、空腹血清C一肽(C.P)、餐后2 h血清C一肽(C-P 2 h)、HbA1C。结果与治疗前比较，住院治疗2周、门诊治疗6个月后两组HbA1c均下降(P<0.05)，空腹血清C-P、C-P 2 h均升高(P均<0.O5)；两组间上述指标比较，P<0.05。结论胰岛素泵（CSI ）与胰岛素多次皮下注射（MSI ）均可改善新发2型糖尿病患者的胰岛功能，但两者相比较，早期应用CSI 能更好的解除高糖毒性，使受损的胰岛B细胞功能逆转，减轻胰岛素抵抗，对患者残余胰岛功能尽早起到保护作用，延缓急慢性并发症的发生发展，值得临床推广应用。
目的比較胰島素泵（CSI ）與胰島素多次皮下註射（MSI ）治療新髮2型糖尿病患者遠期臨床效果。方法將66例初診T2DM住院患者隨機分為兩組，CSI 組與MSI 組，每組33例。CSI 組用胰島素泵持續皮下註射重組人胰島素優必林R，MSI 組予三餐前優必林R，睡前註射長秀霖；治療2週後，改為門診口服降血糖藥物治療6箇月。觀察兩組空腹血糖、空腹血清C一肽(C.P)、餐後2 h血清C一肽(C-P 2 h)、HbA1C。結果與治療前比較，住院治療2週、門診治療6箇月後兩組HbA1c均下降(P<0.05)，空腹血清C-P、C-P 2 h均升高(P均<0.O5)；兩組間上述指標比較，P<0.05。結論胰島素泵（CSI ）與胰島素多次皮下註射（MSI ）均可改善新髮2型糖尿病患者的胰島功能，但兩者相比較，早期應用CSI 能更好的解除高糖毒性，使受損的胰島B細胞功能逆轉，減輕胰島素牴抗，對患者殘餘胰島功能儘早起到保護作用，延緩急慢性併髮癥的髮生髮展，值得臨床推廣應用。
목적비교이도소빙（CSI ）여이도소다차피하주사（MSI ）치료신발2형당뇨병환자원기림상효과。방법장66례초진T2DM주원환자수궤분위량조，CSI 조여MSI 조，매조33례。CSI 조용이도소빙지속피하주사중조인이도소우필림R，MSI 조여삼찬전우필림R，수전주사장수림；치료2주후，개위문진구복강혈당약물치료6개월。관찰량조공복혈당、공복혈청C일태(C.P)、찬후2 h혈청C일태(C-P 2 h)、HbA1C。결과여치료전비교，주원치료2주、문진치료6개월후량조HbA1c균하강(P<0.05)，공복혈청C-P、C-P 2 h균승고(P균<0.O5)；량조간상술지표비교，P<0.05。결론이도소빙（CSI ）여이도소다차피하주사（MSI ）균가개선신발2형당뇨병환자적이도공능，단량자상비교，조기응용CSI 능경호적해제고당독성，사수손적이도B세포공능역전，감경이도소저항，대환자잔여이도공능진조기도보호작용，연완급만성병발증적발생발전，치득림상추엄응용。
objective:compare the long-term clinical effect of continuous subcutaneous insulin infusion(CSI ) and multiple subcutaneous insulin injection(MSI ) on newly diagnosed type 2 diabetes patients. .Methods:66 newly diagnosed type 2 diabetes patients were randomly divided into two groups,CSI group and MSI group,33 cases in each group.CSI group with Recombinant Human Insulin R,MSI group before every mealwith Recombinant Human Insulin R,before sleep with Recombinant Insulin Glargine Injection;after two weeks of treatment,instead of oral hypoglycaemic drugs for 6 months.observe the two groups of fasting plasma glucose,fasting serum C peptide,2h after meals serum C peptide, HBA1C. Results:compare with before treatment,after two weeks and six months treatments,the two groups of HBA1C decreased(P<0.05), fasting serum C peptide and 2h after meals serum C peptide rised(P<0.05).The above indicators between the two groups, P<0.05. Conclusion: CSI and MSI both can impove the islet function of newly diagnosed type 2 diabetes patients,but compared with both,early application of CSI is better to remove sugars toxicity,reverse the damaged islet B cells function,reduce insulin resistance,Protect the resiclual islet function as early,delay the onset of acute or chronic complications,worthy of clinical popularization and application.
